In an exclusive interview with The Fly, KemPharm (KMPH) President and CEO Travis Mickle discussed the recently announced license agreement with an affiliate of Gurnet Point Capital to develop, manufacture and commercialize the former’s product candidates containing serdexmethylphenidate and d-methylphenidate. While the stock… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2967891/-KemPharm-CEO-calls-GPC-absolute-best-partner-in-exclusive-Fly-interview)